At a Glance

Company overview

Company	**CinRock Pharma** Currently conducting multiple animal studies with selective ROCK2 Inhibitors in pulmonary hypertension, HFpEF and other cardiovascular diseases.
Founding Partners	CinRx Pharma and Graviton Bioscience
Target	ROCK2, Rho-associated coiled-coil kinase 2
Programs	Program 1: Pulmonary arterial hypertension (PAH) Program 2: Heart failure with preserved ejection fraction (HFpEF), HCM